Abstract 584P
Background
CNS metastases are associated with high clinical burden and mortality risk in patients with advanced EGFR+ NSCLC. The phase III AENEAS study showed that aumolertinib, a novel third-generation EGFR-TKI, significantly improved median CNS PFS in comparison to gefitinib in treatment-naive EGFR+ NSCLC patients with CNS metastases (29.0 vs 8.3months, hazard ratios: 0.319). In this study, we explore whether aumolertinib could potentially delay or prevent symptomatic CNS metastases in EGFR+ NSCLC patients without baseline CNS metastasis.
Methods
We included all consecutive EGFR+ NSCLC patients who underwent first or second-line aumolertinib treatment without baseline CNS metastasis (April 2021 to February 2023). We estimated the cumulative incidence of subsequent symptomatic CNS metastases, CNS median PFS, and their associated risk factors using the Kaplan–Meier method and the log-rank test. Images obtained upon EGFR-TKI initiation and at the time of EGFR-TKI treatment failure. Follow-up brain scans were not mandatory, typically after the appearance of indicative symptoms. Supplementary follow-up telephone interviews were also employed.
Results
A total of 88 pts were enrolled. At data cutoff,the median follow-up was 21 months,with only 1 pt experienced symptomatic CNS metastases. The cumulative incidence of symptomatic CNS metastasis at 12, 18, and 24 months were 0%, 1.538%, and 1.538%, respectively.For the 62 pts who received second-line aumolertinib,the cumulative incidence of symptomatic CNS metastases at the same time points was 0%. However, the cumulative incidence curves of symptomatic CNS metastasis tended to reach a plateau after approximately 18 months.The cumulative incidence with aumolertinib was lower than historical data from first-generation EGFR-TKIs and also demonstrated a declining trend compared to historical data from the retrospective study of Osimertinib (1-2% at 12 months; 2-3% at 24 months; 11.8% at 36 months).
Conclusions
This is the first study to demonstrate that Aumolertinib can reduce the risk of symptomatic CNS metastasis in EGFR+ NSCLC patients without baseline CNS metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract